Nanobac Pharmaceuticals Company Description
Nanobac Pharmaceuticals wants to pick on something much smaller than its own size. The company is researching nanobacteria, tiny organisms that are 100 times smaller than bacteria, yet apparently cause the body to develop calcium buildup in inconvenient places such as artery walls and kidneys. Such nanobacteria are also called calcifying nano-particles (CNPs) due to their mineralizing properties. Nanobac is researching combinations of already-approved drugs to halt the calcification process. The company also develops and manufactures diagnostic test kits to identify CNPs in the blood. CEO John Stanton controls more than 40% of the company.
View the Comprehensive Company Description for Nanobac Pharmaceuticals
The Company Description provides a historical perspective of Nanobac Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Nanobac Pharmaceuticals's evolution in the marketplace.
